Stock listing
Janux Therapeutics, Inc.
Selected listing: JANX · BX · CHF · CH
Janux Therapeutics, Inc. (BX Swiss: JANX), Health Technology. Latest release Sep 14, 2026: Janux Therapeutics Announces First Patient Dosed in Phase 1 Study…
- Ticker
- BX Swiss: JANX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a public company traded under the ticker JANX in the American market. Janux focuses on developing innovative therapies to address unmet medical needs in cancer treatment.
Latest news from Janux Therapeutics, Inc.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
September 14, 2026
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
August 6, 2026
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 27, 2026
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
April 15, 2026
Research Janux Therapeutics, Inc.
Janux Therapeutics, Inc. company profile
View the public company page for Janux Therapeutics, Inc. on 6ix.
Janux Therapeutics, Inc. news
Read company news and market updates connected to Janux Therapeutics, Inc..
Janux Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Janux Therapeutics, Inc..